ArticleEJNMMI reports2025
Inter-reader agreement and additive benefit of SPECT or SPECT/CT modality with [
Article in EJNMMI reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIM/
introductionIn central Europe, up to 76% of population exhibit thyroid nodules (TN). The combination of ultrasound findings and thyroid scan imaging are supposed to ensure a cost-effective and reliable prediction of malignancy risk. However, real-world impact of ultrasound findings, i.e. TI-RADS, has raised concerns due to its highly limited reliability and reproducibility. The recent advancements and increasing access of SPECT/CT scanners might contribute to thyroid management. This study aimed to elucidate additive value of SPECT(-CT) imaging in initial evaluation of complex TN cases, particularly on multinodular goiter and difficult-to-characterize solitary nodules. MATERIALS AND
methodsA total of 61 patients (19 males and 42 females with a mean age of 56 (± 17)) with incidental TN were retrospectively enrolled in this study between November 2022 and July 2023, who underwent both conventional planar thyroid scan and SPECT(-CT) imaging. Three readers with varying experience level selected a target nodule within thyroid gland and evaluated its functionality, ACR TI-RADS categorization and additive benefit of SPECT(-/CT) imaging. Kappa-value for inter-reader agreement (IRA) was interpreted as follows: < 0.01-0.20, slight agreement; 0.21-0.40, fair agreement; 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement; and 0.81-1.00; almost perfect agreement.
resultsOf the target TNs, 33 (54%) were located in the left thyroid lobe, 5 (8%) in the isthmus and the remaining target TNs (38%) in the right lobe. The median target TN size was 20 mm (10-59). The target nodule match rate among readers was almost perfect (k-value 0.81; 95% CI: 0.72-0.90). The IRA regarding ACR TI-RADS was moderate with k-value of 0.47 (95% CI: 0.40-0.54). The IRA regarding patient referral was substantial among readers with k-value of 0.60, while k-value was even higher at pairwise comparison of experienced readers (k-value: 0.64). IRA regarding the target TN functionality among readers was good with k-value of 0.68 (95%CI: 0.59-0.77). IRA involving the less experienced reader revealed only slightly lower reliability scores, i.e. a k-value of 0.61. The correlation with ground truth results revealed comparable results among experienced and less-experienced readers.
conclusionIncreasing clinical experience of physicians appeared to have a direct correlation with a higher referral rate of SPECT(-CT) imaging, although the additive clinical benefit was only evident for a minority of patients. Hence, SPECT(-CT) imaging might be more suitable for tertiary care centers, as its additive benefit at primary care level would have only negligible effect for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.